查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924638

Carbetocin注射市场依适应症、给药途径、最终用户和销售管道划分－2026-2032年全球预测

Carbetocin for Injection Market by Indication, Route Of Administration, End User, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年Carbetocin注射市场价值为 2.5975 亿美元，预计到 2026 年将成长至 2.9533 亿美元，到 2032 年将达到 5.9391 亿美元，复合年增长率为 12.54%。

关键市场统计数据
基准年 2025 2.5975亿美元
预计年份：2026年 2.9533亿美元
预测年份 2032 5.9391亿美元
复合年增长率 (%) 12.54%

关于Carbetocin注射的权威意见，其在孕产妇保健流程中的临床作用，以及影响相关人员决策的策略考量

Carbetocin注射因其催产作用和在产科操作中的诸多优势，临床应用日益广泛，已成为现代孕产妇保健中一项重要的药物干预措施。Carbetocin是一种合成催产素类似物，用于预防和治疗产后出血，其药理特性影响分娩中心、医院和诊所的采购决策。该产品的製剂形式和包装选择会影响现场给药、低温运输物流和废弃物管理，所有这些都是生产商、支付方和医疗服务提供者需要考虑的策略因素。

不断发展的临床指南、包装技术的进步以及分销系统的重新设计如何重塑Carbetocin素注射液的使用模式和供应可靠性

Carbetocin注射的市场环境正经历变革时期，临床指南的完善、生产技术的创新以及采购政策的调整共同推动其市场应用趋势的转变。临床实务指引日益强调将子宫收缩剂作为产后出血多模式介入方案的一部分，这项临床重点促使产品研发人员优先考虑产品的稳定性、易用性和安全性，从而减少对低温运输基础设施的依赖。同时，预填充式注射器生产和无菌填充技术的进步，为减少剂量误差和简化资源匮乏环境下的给药流程创造了机会。

评估 2025 年美国关税如何改变了Carbetocin注射供应链的采购结构、定价动态和供应链韧性。

美国关税于2025年生效，其累积影响已造成持续的成本和营运压力，相关人员必须在製造、分销和采购活动中对此进行评估。关税提高了进口原料药和专用包装组件的到岸成本，迫使依赖全球供应链的製造商重新评估其筹资策略并加速供应商多元化。为此，一些生产商尽可能将订单转移到国内供应商，而另一些生产商则与非美国合作伙伴签订了长期承购协议，以缓解短期成本波动。

基于深度细分观点，揭示通路、医疗机构、适应症、包装和产品类型对Carbetocin注射剂获取和采购行为的影响

透过对Carbetocin注射剂进行細項分析，我们考虑了不同分销管道的通路、最终用户、适应症、包装和产品类型，从而揭示了其在商业性和临床方面的细微差别。通路涵盖医院药房系统（包括公立和私立医院药房）、零售药房网路（包括连锁药局和独立药局）以及线上药局，扩大了药品的可及性。每个管道都有其独特的采购週期和品质要求，这些都会影响製造商的市场推广策略和包装选择。

从区域比较观点影响Carbetocin注射剂全球取得和部署的监管复杂性、采购行为和供应链策略

美洲、欧洲、中东和非洲以及亚太地区Carbetocin的区域趋势具有不同的战略意义。每个地区都受到不同的监管路径、孕产妇健康优先事项和供应链格局的影响。在美洲，采购很大程度上受到综合医院系统和国家采购组织的限制，这些机构优先考虑成本效益和供应商可靠性。同时，私人支付方和公共卫生计画则在降低孕产妇死亡率的倡议和按绩效付费的采购框架下评估卡贝缩宫素注射液的应用。

製造商和供应商如何利用生产规模、包装创新和策略伙伴关係来确保Carbetocin素注射液的采购和临床应用信心

Carbetocin注射领域主要企业的行动反映了其围绕生产规模、包装创新和产品系列多元化的策略定位。现有药物研发公司致力于透过投资专有包装技术来保护产品价值，这些技术能够确保临床证据的生成、製剂的稳定性以及在各种医疗环境中安全给药。这些公司通常透过强调品管系统、完善的药物监测程序以及与医院系统合作以确保长期供应协议来追求差异化定位。

针对生产商、支付者和医疗系统的具体策略行动，旨在增强Carbetocin注射的供应韧性，加速临床应用，并提升其商业性表现。

产业领导者应采取一系列切实可行的措施，以增强Carbetocin素注射液的供应韧性，改善病患用药途径，并优化其商业性表现。首先，投资活性成分和关键包装组件的双源筹资策略，将降低关税引发的成本飙升和单一来源供应中断的风险。同时，对区域製造地进行长期投资，将有助于缩短前置作业时间，并提高监管一致性。其次，优先开发预填充式注射器并改进无菌填充工艺，将降低给药的复杂性，并使该产品在资源丰富的综合性医院和资源有限的妇产中心都能获得良好的市场地位。

结合临床文献回顾、关键相关人员访谈和情境建模的混合方法证据基础，确保了对Carbetocin注射的可靠实践知识。

本研究采用混合方法，结合系统性的二手资料研究、有针对性的一手访谈和严谨的综合分析，旨在得出关于Carbetocin素注射液的可操作性结论。二手资料分析包括对同行评审的临床文献（关于宫缩抑製剂的疗效和安全性）、与製剂和包装相关的监管文件和核准，以及影响医院和国家采购行为的公共采购指南的回顾。这些资讯来源为评估商业性和营运趋势奠定了临床和政策背景的基础。

将策略意义和营运重点相结合，这将决定Carbetocin注射的给药形式，从而实现持续的临床疗效和采购成功。

总之，Carbetocin注射剂凭藉其临床特性以及先进包装和稳定配方带来的操作优势，在预防和控制产后出血方面占据着重要的战略地位。多种因素正在重塑市场环境：不断更新的临床指南优先考虑有效的子宫收缩剂；包装和生产技术的创新简化了给药流程；分销渠道的转变改变了获取途径；以及关税变化等外部压力正在重塑供应链。积极应对这些趋势的相关人员——例如投资于健全的采购系统、创新包装技术以及积累有针对性的临床证据——将更有利于获得采购合同，并保障患者的持续用药。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Carbetocin宫素注射液市场（依适应症划分）

  • 预防产后出血
  • 治疗产后出血
  • 堕胎和流产管理

第九章Carbetocin宫素注射剂市场，依给药途径划分

  • 静脉注射
    • Bolus注
    • 短期滴注
  • 肌肉内注射
    • 单点注射
    • 多剂量方案
  • 联合治疗
    • 静脉注射和肌肉注射的顺序组合给药
    • 基于通讯协定的联合治疗

第十章 依最终用户分類的Carbetocin注射市场

  • 医院
  • 门诊手术中心

第十一章Carbetocin缩宫素注射市场（依销售管道划分）

  • 机构采购
    • 直接从医院购买
    • 集团采购组织
  • 竞标和公共采购
    • 中央政府竞标
    • 多边和捐助者资助的项目
  • 零售药房
    • 连锁药局
    • 独立药房
  • 线上药局和批发商

第十二章Carbetocin注射剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章Carbetocin宫素注射市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国Carbetocin注射剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国Carbetocin注射市场

第十六章 中国Carbetocin宫素注射剂市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • AstraZeneca PLC
  • Bayer AG
  • Biocon Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Emcure Pharmaceuticals Limited
  • Endo International plc
  • Ferring Pharmaceuticals AG
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Gland Pharma Limited
  • GlaxoSmithKline PLC
  • Hetero Labs Limited
  • Hoffmann-La Roche AG
  • Intas Pharmaceuticals Limited
  • Johnson & Johnson
  • Macleods Pharmaceuticals Pvt. Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-7A380DA7C3EE

The Carbetocin for Injection Market was valued at USD 259.75 million in 2025 and is projected to grow to USD 295.33 million in 2026, with a CAGR of 12.54%, reaching USD 593.91 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 259.75 million
Estimated Year [2026] USD 295.33 million
Forecast Year [2032] USD 593.91 million
CAGR (%) 12.54%

An authoritative orientation to carbetocin injection, its clinical role in maternal care pathways, and the strategic considerations shaping stakeholder decision-making

Carbetocin for injection has emerged as a pivotal pharmaceutical intervention in contemporary maternal health, with growing clinical adoption driven by its uterotonic efficacy and operational advantages in obstetric settings. As a synthetic oxytocin analogue, carbetocin is used to prevent and treat postpartum hemorrhage, and its pharmacologic profile has influenced procurement decisions across birthing centers, hospitals, and clinics. The product's formulation options and packaging choices affect frontline administration, cold chain logistics, and waste management, all of which translate into strategic considerations for manufacturers, payers, and healthcare providers.

Stakeholders must navigate a landscape defined by evolving clinical guidelines, varied regulatory frameworks, and competitive pressures between originator and generic manufacturers. This report situates carbetocin within that broader context, highlighting how distribution channels such as hospital pharmacy networks, retail and online pharmacies, and the nuanced structure of public and private hospital procurement shape patient access. By examining packaging types from ampoules to prefilled syringes and the implications of single-dose and multi-dose formats, this analysis frames the decision levers that influence clinical uptake, supply resilience, and cost-efficiency in maternal care pathways.

Consequently, the introduction sets the stage for a deeper review of market forces, regulatory shifts, and operational strategies that are reshaping how carbetocin is produced, packaged, and delivered to patients across healthcare settings.

How evolving clinical guidelines, packaging technologies, and distribution redesigns are collectively reshaping adoption patterns and supply reliability for carbetocin injection

The landscape for carbetocin for injection is undergoing transformative shifts driven by clinical guideline refinements, manufacturing innovations, and changes in procurement preferences that together alter adoption dynamics. Clinical practice guidelines increasingly emphasize uterotonic choice as part of a bundle of interventions for postpartum hemorrhage management, and this clinical focus has incentivized product developers to prioritize stability, ease of administration, and safety profiles that reduce reliance on cold chain infrastructure. In parallel, technological advances in prefilled syringe production and sterile filling techniques have created opportunities to reduce dosing errors and to streamline administration in resource-constrained settings.

At the same time, distribution models are adapting; hospital pharmacy procurement is becoming more centralized while online pharmacy channels expand options for outpatient and community-level access. Public health programs and private payers are reassessing formularies, favoring products that balance clinical effectiveness with predictable supply. Manufacturers respond through strategic partnerships with contract manufacturers, investments in packaging innovation, and differentiated branding strategies to support both originator and generic portfolios. These shifts interact with regulatory harmonization efforts that aim to standardize approval pathways and pharmacovigilance expectations, creating both friction and openings for manufacturers that can demonstrate robust quality systems and supply reliability.

Together, these trends indicate a market in transition where clinical evidence, packaging technology, and distribution redesign combine to influence which products gain enduring traction in maternal health systems.

Assessment of how United States tariff actions in 2025 reshaped sourcing, pricing dynamics, and supply chain resilience across the carbetocin injection ecosystem

The cumulative impact of United States tariffs enacted in 2025 has introduced a sustained set of cost and operational pressures that stakeholders must assess across manufacturing, distribution, and procurement activities. Tariff measures increased landed costs for imported active pharmaceutical ingredients and specialized packaging components, prompting manufacturers that rely on global supply chains to re-evaluate sourcing strategies and to accelerate supplier diversification. In response, some producers have shifted orders toward domestic suppliers where feasible, while others have entered long-term off-take arrangements with non-U.S. partners to mitigate near-term cost volatility.

These changes have had downstream effects for hospital and retail procurement teams, which faced intensified price negotiation dynamics and the need to reassess inventory strategies to buffer against supply disruptions. Procurement officers increasingly prioritized suppliers with transparent cost structures and resilient logistics networks, favoring partners that demonstrated ability to absorb tariff impacts or to offer alternative packaging solutions that reduce overall landed costs. Simultaneously, regulatory agencies and health systems grew more focused on ensuring that tariff-related adjustments did not compromise product quality or access, leading to heightened scrutiny of import documentation and more rigorous inspection protocols at points of entry.

Consequently, the tariff environment catalyzed a rebalancing of supply chain risk management: manufacturers and distributors adapted contracts and inventory policies, while clinical administrators recalibrated purchasing strategies to preserve continuity of care for postpartum hemorrhage prevention and treatment.

Deep segmentation-driven perspectives that reveal how distribution channels, care settings, indications, packaging, and product type influence access and procurement behavior for carbetocin injection

Segmentation analysis for carbetocin for injection reveals nuanced commercial and clinical implications when considered across distribution channel, end user, indication, packaging type, and product type. Distribution channels range from hospital pharmacy systems-including government and private hospital pharmacy operations-to retail pharmacy networks that comprise chain and independent outlets, and increasingly to online pharmacies that enable broader access. Each channel presents distinct procurement cycles and quality expectations, which influence manufacturer go-to-market tactics and packaging preferences.

End users span birthing centers, clinics, and hospitals; birthing centers themselves vary between hospital-affiliated units and standalone facilities, while clinics include general practice settings and maternity-specific clinics. These distinctions shape administration settings and staff training requirements, informing choices between ampoule-based formats and prefilled syringes. Indications divide into prevention of postpartum hemorrhage and treatment of postpartum hemorrhage; preventive use often aligns with scheduled cesarean sections and routine management of vaginal deliveries, whereas treatment use must address active and severe hemorrhage scenarios, demanding rapid availability and dosing reliability.

Packaging type considerations encompass ampoules versus prefilled syringes, with ampoules further delineated into multi-dose and single-dose formats and prefilled syringe options subdividing into glass and plastic constructs; these variables affect cold chain, sharps waste management, and ease of use in high-pressure clinical events. Product type differentiates originator formulations from generic offerings, with generics further split into branded generics and unbranded generics, creating layered competitive dynamics driven by procurement policy, perceived quality, and price sensitivity. Integrating these segmentation lenses enables stakeholders to tailor product development, supply planning, and clinical education to the operational realities of each care setting.

Comparative regional perspectives on regulatory complexity, procurement behaviors, and supply chain strategies that determine access and deployment of carbetocin injection globally

Regional dynamics for carbetocin for injection present distinct strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific, each influenced by differing regulatory pathways, maternal health priorities, and supply chain footprints. In the Americas, procurement tends to be influenced by consolidated hospital systems and national purchasing organizations that emphasize cost-effectiveness and supplier reliability, while private payers and public health programs evaluate adoption in the context of maternal mortality reduction initiatives and performance-based procurement frameworks.

Across Europe, the Middle East and Africa, regulatory complexity and infrastructure variance lead to differentiated demand drivers; high-capacity health systems often prioritize advanced packaging and product differentiation, whereas resource-constrained settings value thermostability and simplified administration. This regional diversity incentivizes manufacturers to adopt tiered product strategies and to develop targeted partnerships with regional distributors and public health agencies to support broader access.

In the Asia-Pacific region, a combination of strong domestic manufacturing capacity and large public procurement programs creates both competitive pressures and opportunities for scaled deployment. Manufacturers focusing on this region emphasize cost-effective production, local regulatory alignment, and adaptable logistics solutions to meet diverse clinical settings ranging from tertiary hospitals to rural birthing centers. Across all regions, stakeholders must balance regulatory compliance, procurement timelines, and clinical training programs to enable reliable and equitable access to carbetocin for postpartum hemorrhage management.

How manufacturers and suppliers are leveraging manufacturing scale, packaging innovation, and strategic partnerships to secure procurement wins and clinical trust in carbetocin injection

Corporate behavior among key players in the carbetocin injection space reflects strategic positioning around manufacturing scale, packaging innovation, and portfolio diversification. Established originator companies have sought to protect product value through investments in clinical evidence generation, formulation stability, and proprietary packaging that facilitate safe administration in diverse care settings. These firms typically pursue differentiated positioning by emphasizing quality control systems, established pharmacovigilance programs, and partnerships with hospital systems to secure long-term supply agreements.

Generic manufacturers and branded generics firms pursue scale efficiencies and competitive pricing while attempting to demonstrate equivalence in quality and supply reliability. Many have invested in contract manufacturing arrangements and in sterile filling technologies that enable production of both ampoules and prefilled syringe formats. Suppliers that combine robust manufacturing footprints with flexible packaging capabilities have been better positioned to respond to procurement tenders and to meet rapid-deployment needs of public health initiatives.

Across the supplier base, strategic moves include vertical integration to control key input streams, targeted M&A to acquire specialized filling capacity, and collaborative engagements with health systems to pilot new delivery formats. Companies that transparently address supply chain risk, demonstrate rapid regulatory responsiveness, and invest in clinician-focused education on administration protocols tend to achieve stronger positioning among hospital pharmacy decision-makers and public procurement bodies.

Concrete strategic actions for manufacturers, payers, and health systems to enhance supply resilience, clinical adoption, and commercial performance for carbetocin injection

Industry leaders should pursue a set of actionable measures to strengthen supply resilience, improve patient access, and optimize commercial performance for carbetocin for injection. First, investing in dual-sourcing strategies for active ingredients and critical packaging components will reduce exposure to tariff-induced cost shocks and single-source interruptions, while longer-term investments in regional manufacturing hubs can shorten lead times and enhance regulatory alignment. Second, prioritizing prefilled syringe development and sterile filling process improvements reduces administration complexity and positions products favorably in both high-resource tertiary hospitals and lower-resource birthing centers.

Third, align clinical evidence generation with payer and procurement needs by sponsoring pragmatic studies that document real-world outcomes related to ease of use, dosing accuracy, and reduced wastage. Fourth, strengthen engagement with hospital pharmacy and procurement teams through outcome-based contracting pilots and supply guarantees that address inventory volatility concerns. Fifth, design differentiated go-to-market strategies for originator and generic portfolios, leveraging branded generics where appropriate to capture trust while offering value-driven unbranded options for large-scale public procurement.

Finally, integrate comprehensive risk management practices that combine scenario planning, inventory optimization, and transparent supplier auditing to maintain continuity of care during geopolitical or tariff-related disruptions. Implementing these steps will enhance market resilience and support broader clinical adoption across diverse healthcare settings.

A mixed-methods evidence base combining clinical literature review, primary stakeholder interviews, and scenario modeling to ensure robust and actionable insights into carbetocin injection

This research applied a mixed-methods approach that combined systematic secondary research, targeted primary interviews, and rigorous synthesis to produce actionable insights on carbetocin for injection. Secondary analysis included review of peer-reviewed clinical literature on uterotonic efficacy and safety, regulatory dossiers and approvals related to formulation and packaging, and public procurement guidelines that influence hospital and national purchasing behavior. These sources established a foundation of clinical and policy context against which commercial and operational trends were evaluated.

Primary research involved structured interviews with supply chain managers, hospital pharmacy directors, clinical practitioners involved in obstetrics, and regulatory affairs specialists to capture real-world operational considerations and procurement decision criteria. These conversations provided qualitative validation of distribution channel dynamics, packaging preferences, and the practical implications of tariff-induced cost pressures. Supply chain modeling and scenario analysis were used to assess the potential impact of sourcing shifts and tariff developments on lead times and inventory needs, while triangulation across data sources ensured robustness of conclusions.

Finally, findings were stress-tested through expert review sessions to identify potential blind spots and to refine recommendations. Transparency of methods, alignment with clinical guidelines, and incorporation of pragmatic stakeholder perspectives underpin the credibility and practical utility of the research.

Synthesis of strategic implications and the operational priorities that will determine which carbetocin injection offerings deliver sustained clinical impact and procurement success

In conclusion, carbetocin for injection occupies a strategically important position in efforts to prevent and manage postpartum hemorrhage, driven by its clinical attributes and the operational benefits of advanced packaging and stable formulations. The market environment is being reshaped by converging forces: evolving clinical guidance that prioritizes effective uterotonics, packaging and manufacturing innovations that streamline administration, distribution channel shifts that change access pathways, and external pressures such as tariff changes that prompt supply chain realignment. Stakeholders who proactively address these dynamics-by investing in resilient sourcing, packaging innovation, and targeted clinical evidence-will be better positioned to secure procurement commitments and to support consistent patient access.

Looking ahead, coordinated efforts among manufacturers, healthcare providers, and procurement bodies are essential to translate product capabilities into measurable improvements in maternal outcomes. Strategic emphasis on supply reliability, clinician training, and adaptable product portfolios that reflect the diverse needs of birthing centers, clinics, and hospitals will determine which products achieve broad and sustained clinical use. In sum, a combination of operational rigor, clinical alignment, and adaptive commercial strategies will underpin success in the evolving carbetocin ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Carbetocin for Injection Market, by Indication

  • 8.1. Postpartum Hemorrhage Prevention
  • 8.2. Postpartum Hemorrhage Treatment
  • 8.3. Pregnancy Termination And Miscarriage Management

9. Carbetocin for Injection Market, by Route Of Administration

  • 9.1. Intravenous
    • 9.1.1. Bolus Injection
    • 9.1.2. Short Infusion
  • 9.2. Intramuscular
    • 9.2.1. Single Site Injection
    • 9.2.2. Multiple Dose Regimens
  • 9.3. Combined Regimens
    • 9.3.1. Sequential Intravenous And Intramuscular
    • 9.3.2. Protocol-Driven Combination Regimens

10. Carbetocin for Injection Market, by End User

  • 10.1. Hospitals
  • 10.2. Ambulatory Surgical Centers

11. Carbetocin for Injection Market, by Sales Channel

  • 11.1. Institutional Procurement
    • 11.1.1. Direct Hospital Purchasing
    • 11.1.2. Group Purchasing Organizations
  • 11.2. Tender And Public Procurement
    • 11.2.1. Central Government Tenders
    • 11.2.2. Multilateral And Donor-Funded Programs
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies
  • 11.4. Online Pharmacies And Distributors

12. Carbetocin for Injection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Carbetocin for Injection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Carbetocin for Injection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Carbetocin for Injection Market

16. China Carbetocin for Injection Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Alembic Pharmaceuticals Limited
  • 17.8. AstraZeneca PLC
  • 17.9. Bayer AG
  • 17.10. Biocon Limited
  • 17.11. Cipla Limited
  • 17.12. Dr. Reddy's Laboratories Limited
  • 17.13. Emcure Pharmaceuticals Limited
  • 17.14. Endo International plc
  • 17.15. Ferring Pharmaceuticals AG
  • 17.16. Fresenius Kabi AG
  • 17.17. Gilead Sciences, Inc.
  • 17.18. Gland Pharma Limited
  • 17.19. GlaxoSmithKline PLC
  • 17.20. Hetero Labs Limited
  • 17.21. Hoffmann-La Roche AG
  • 17.22. Intas Pharmaceuticals Limited
  • 17.23. Johnson & Johnson
  • 17.24. Macleods Pharmaceuticals Pvt. Ltd.
  • 17.25. Merck & Co., Inc.
  • 17.26. Novartis AG
  • 17.27. Pfizer Inc.
  • 17.28. Sun Pharmaceutical Industries Limited
  • 17.29. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARBETOCIN FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARBETOCIN FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY POSTPARTUM HEMORRHAGE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PREGNANCY TERMINATION AND MISCARRIAGE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PREGNANCY TERMINATION AND MISCARRIAGE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PREGNANCY TERMINATION AND MISCARRIAGE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY BOLUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY BOLUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SHORT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SHORT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SHORT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SINGLE SITE INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SINGLE SITE INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SINGLE SITE INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTIPLE DOSE REGIMENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTIPLE DOSE REGIMENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTIPLE DOSE REGIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SEQUENTIAL INTRAVENOUS AND INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SEQUENTIAL INTRAVENOUS AND INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SEQUENTIAL INTRAVENOUS AND INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PROTOCOL-DRIVEN COMBINATION REGIMENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PROTOCOL-DRIVEN COMBINATION REGIMENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY PROTOCOL-DRIVEN COMBINATION REGIMENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY DIRECT HOSPITAL PURCHASING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY DIRECT HOSPITAL PURCHASING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY DIRECT HOSPITAL PURCHASING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY GROUP PURCHASING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY GROUP PURCHASING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY GROUP PURCHASING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CENTRAL GOVERNMENT TENDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CENTRAL GOVERNMENT TENDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CENTRAL GOVERNMENT TENDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTILATERAL AND DONOR-FUNDED PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTILATERAL AND DONOR-FUNDED PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY MULTILATERAL AND DONOR-FUNDED PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY ONLINE PHARMACIES AND DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY ONLINE PHARMACIES AND DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY ONLINE PHARMACIES AND DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 223. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 227. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 234. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 238. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 239. NATO CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL CARBETOCIN FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY COMBINED REGIMENS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY INSTITUTIONAL PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY TENDER AND PUBLIC PROCUREMENT, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA CARBETOCIN FOR INJECTION MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)